» Articles » PMID: 36508283

Novel Risk Assessment for the Intensity of Conditioning Regimen In older Patients

Abstract

Reduced-intensity conditioning (RIC) regimens have long-term outcomes that are generally comparable with those of myeloablative conditioning (MAC) because of a lower risk of nonrelapse mortality (NRM) but a higher risk of relapse. However, it is unclear how we should select the conditioning intensity in individual cases. We propose the risk assessment for the intensity of conditioning regimen in elderly patients (RICE) score. We retrospectively analyzed 6147 recipients aged 50 to 69 years using a Japanese registry database. Based on the interaction analyses, advanced age (≥60 years), hematopoietic cell transplantation-specific comorbidity index (≥2), and umbilical cord blood were used to design a scoring system to predict the difference in an individual patient's risk of NRM between MAC and RIC: the RICE score, which is the sum of the 3 factors. Zero or 1 implies low RICE score and 2 or 3, high RICE score. In multivariate analyses, RIC was significantly associated with a decreased risk of NRM in patients with a high RICE score (training cohort: hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.60-0.90; P = .003; validation cohort: HR, 0.57; 95% CI, 0.43-0.77; P < .001). In contrast, we found no significant differences in NRM between MAC and RIC in patients with a low RICE score (training cohort: HR, 0.99; 95% CI, 0.85-1.15; P = .860; validation cohort: HR, 0.81; 95% CI, 0.66-1.01; P = .061). In summary, a new and simple scoring system, the RICE score, appears to be useful for personalizing the conditioning intensity and could improve transplant outcomes in older patients.

Citing Articles

Myeloablative conditioning in cord blood transplantation for acute myeloid leukemia patients is efficacious only until age 55.

Oshima S, Arai Y, Kondo T, Yano S, Hirabayashi S, Uchida N Bone Marrow Transplant. 2025; .

PMID: 39838078 DOI: 10.1038/s41409-025-02508-2.

References
1.
Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick E . Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood.... Transplant Cell Ther. 2020; 27(1):68.e1-68.e9. PMC: 8015679. DOI: 10.1016/j.bbmt.2020.09.026. View

2.
Kanda J, Brazauskas R, Hu Z, Kuwatsuka Y, Nagafuji K, Kanamori H . Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Transplant. 2016; 22(4):744-751. PMC: 4801761. DOI: 10.1016/j.bbmt.2015.12.027. View

3.
Gagelmann N, Kroger N . Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?. Haematologica. 2021; 106(7):1794-1804. PMC: 8252938. DOI: 10.3324/haematol.2020.268839. View

4.
Flynn C, Hirsch B, DeFor T, Barker J, Miller J, Wagner J . Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol. 2007; 82(10):867-72. DOI: 10.1002/ajh.20989. View

5.
Sorror M, Storb R, Sandmaier B, Maziarz R, Pulsipher M, Maris M . Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014; 32(29):3249-56. PMC: 4178523. DOI: 10.1200/JCO.2013.53.8157. View